Nrf2 Regulates β-Cell Mass by Suppressing β-Cell Death and Promoting β-Cell Proliferation
Author(s) -
Sharon Baumel-Alterzon,
Liora S. Katz,
Gabriel Brill,
Clairete Jean-Pierre,
Yansui Li,
Isabelle Tse,
Shyam Biswal,
Adolfo GarcíaOcaña,
Donald K. Scott
Publication year - 2022
Publication title -
diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.219
H-Index - 330
eISSN - 1939-327X
pISSN - 0012-1797
DOI - 10.2337/db21-0581
Subject(s) - cell growth , cell , microbiology and biotechnology , apoptosis , programmed cell death , islet , biology , in vivo , pdx1 , conditional gene knockout , chemistry , endocrinology , diabetes mellitus , phenotype , biochemistry , gene
Finding therapies that can protect and expand functional β-cell mass is a major goal of diabetes research. Here, we generated β-cell–specific conditional knockout and gain-of-function mouse models and used human islet transplant experiments to examine how manipulating Nrf2 levels affects β-cell survival, proliferation, and mass. Depletion of Nrf2 in β-cells results in decreased glucose-stimulated β-cell proliferation ex vivo and decreased adaptive β-cell proliferation and β-cell mass expansion after a high-fat diet in vivo. Nrf2 protects β-cells from apoptosis after a high-fat diet. Nrf2 loss of function decreases Pdx1 abundance and insulin content. Activating Nrf2 in a β-cell–specific manner increases β-cell proliferation and mass and improves glucose tolerance. Human islets transplanted under the kidney capsule of immunocompromised mice and treated systemically with bardoxolone methyl, an Nrf2 activator, display increased β-cell proliferation. Thus, by managing reactive oxygen species levels, Nrf2 regulates β-cell mass and is an exciting therapeutic target for expanding and protecting β-cell mass in diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom